CTLA4 and cancer: In a single-center retrospective cohort study, the analysis of brain damage markers S100 calcium-binding protein B (S100B) and NfL concentration in blood showed high sensitivity and specificity for early detection and monitoring of CNS irAEs in cancer patients treated with combined CTLA-4 and PD-1 blockage (41).